Healthcare / BiotechnologyNasdaqGM
$28.25
-0.98 (-3.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-178.9M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$468M
P/E
N/A
•EV/EBITDA
N/A
•ROE
144.3%
↑Gross Margin
N/A
•Debt/Equity
-0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+6.2%
FCF CAGR
—
FCF margin
-174.6%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $102.5M · net income $-191.1M · FCF $-178.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $102.5M | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $42.7M | $42.7M | $38.4M | $51.7M | $59.7M |
| Net Income | $-191.1M | $-191.1M | $-227.5M | $-106.8M | $-119.2M | $-105.5M | $-32.1M | $-119.2M | $-35.3M | $-19.7M | $1.7M |
| EBITDA | $-141.8M | $-141.8M | $-186.8M | $-58.0M | $-107.7M | $-93.7M | $-66.8M | $-50.7M | $-32.7M | $-14.3M | $7.0M |
| EPS | -22.49 | -22.49 | -29.40 | -17.80 | -23.50 | -22.90 | -9.90 | — | — | — | — |
| Operating Margin | -102.4% | -102.4% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | -129.8% | -96.9% | -37.2% | 2.3% |
| Net Margin | -186.5% | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | -278.9% | -91.9% | -38.1% | 2.8% |
| Balance Sheet | |||||||||||
| Debt/Equity | -0.12 | -0.12 | 0.52 | 0.22 | 0.23 | 0.06 | 0.07 | 0.09 | 0.08 | — | — |
| Current Ratio | 2.01 | 2.01 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-178.9M | $-178.9M | $-194.6M | $-115.9M | $-4.3M | — | — | — | $11.1M | $-40.4M | $-17.5M |
| Returns | |||||||||||
| ROE | 144.3% | 144.3% | -510.0% | -71.4% | -54.9% | -41.8% | -9.7% | -121.9% | -26.8% | 18.1% | -1.9% |
| Valuation | |||||||||||
| P/B | — | — | 3.38 | 1.40 | 1.92 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 65.2% | 65.2% | -59.6% | 126.8% | — | 44.8% | -0.0% | 11.2% | -25.7% | -13.4% | — |
| EPS Growth | 23.5% | 23.5% | -65.2% | 24.3% | — | -131.3% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+213.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-29.40 → -22.49
Residual
+213.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.